The main aplastic anemia treatments are hematopoietic stem cell transplantation, which can cure the disease, and immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine, now usually combined with eltrombopag. Both rest on a foundation of supportive care with transfusions and infection prevention. This comprehensive overview of aplastic anemia treatments explains how doctors choose between them, what each involves, and what to expect afterward.
In my practice, the choice usually comes down to three questions: how severe the marrow failure is, how old and fit the patient is, and whether a well-matched donor is available. Before any of that, though, we must be sure the diagnosis is right.
What Aplastic Anemia Is
Aplastic anemia is a rare hematological disorder in which the bone marrow stops making enough red cells, white cells, and platelets. The marrow is not invaded by cancer; it is simply empty, with blood-forming stem cells largely replaced by fat.
In most acquired cases, the cause is an immune attack: the patient’s own T cells target and suppress the blood stem cells. That is why drugs that calm the immune system can work. Other triggers include certain medications, benzene and other toxic chemicals, radiation, and some viral infections such as hepatitis. Many cases are idiopathic, with no identifiable cause.
A minority are inherited, most notably Fanconi anemia and dyskeratosis congenita. Recognizing these matters because immunosuppression does not help them and transplant conditioning must be adjusted.
Diagnosis and Severity: The Starting Point for Treatment
Symptoms follow from low counts: fatigue, pallor, and breathlessness from anemia; infections from low neutrophils; and bruising, nosebleeds, or gum bleeding from low platelets. A complete blood count shows pancytopenia, and a bone marrow biopsy shows a hypocellular marrow without abnormal cells, which separates aplastic anemia from other hematologic disorders such as hypocellular myelodysplastic syndrome.
Additional tests look for inherited causes (chromosome breakage testing, telomere length), a PNH clone by flow cytometry, viral infections, and vitamin deficiencies. Severity is then graded using standard criteria:
| Severity | Marrow | Blood counts (at least two of the following) |
|---|---|---|
| Non-severe | Hypocellular | Low counts that do not meet the severe criteria |
| Severe | Cellularity under 25% | Neutrophils under 0.5 x 10^9/L; platelets under 20 x 10^9/L; reticulocytes under 20 x 10^9/L (some guidelines use 60 x 10^9/L with automated counts) |
| Very severe | As for severe | As for severe, with neutrophils under 0.2 x 10^9/L |
Severe and very severe disease need definitive treatment promptly. Non-severe disease may be monitored if counts are stable and the patient is not transfusion-dependent.
Supportive Care: The Foundation
Every patient needs supportive care while definitive treatment takes effect, which can take months. The key elements are:
- Red cell transfusions for symptomatic anemia and platelet transfusions for bleeding or very low counts. Blood products are usually leukocyte-reduced and irradiated.
- Avoiding family-donor transfusions in potential transplant candidates, to reduce the risk of sensitization against a future donor.
- Infection prevention, including prompt antibiotics for any fever and, in severe neutropenia, preventive antifungal and antiviral drugs.
- Iron chelation for people who have received many transfusions and developed iron overload.
Hematopoietic Stem Cell Transplantation
Stem cell transplantation replaces the failed marrow with healthy donor stem cells and is the only established cure. It is generally the first choice for younger patients with severe disease who have an HLA-matched sibling donor, and it is the standard for inherited forms, where it is the only treatment for aplastic anemia that corrects the underlying marrow defect.
When no sibling is available, matched unrelated donors and, increasingly, haploidentical (half-matched family) donors are options, particularly for children and young adults or when immunosuppression has failed. The risks include graft failure, infection, and graft-versus-host disease (GVHD), so conditioning regimens for aplastic anemia are designed to be less toxic than those used for leukemia.
Immunosuppressive Therapy and Eltrombopag
For patients who are older, lack a suitable donor, or prefer to avoid transplant, immunosuppressive therapy (IST) is the standard. It combines horse ATG, given by infusion over several days in hospital, with oral cyclosporine continued for many months. ATG removes the T cells attacking the marrow; cyclosporine keeps the immune response suppressed.
Eltrombopag, an oral thrombopoietin receptor agonist, stimulates the remaining stem cells. Adding it to ATG and cyclosporine has become standard first-line IST in many centers because it improves the speed and depth of response. It can also help some patients whose disease did not respond to IST alone, supporting the recovery of bone marrow function.
Response to IST is slow, typically becoming apparent over three to six months. Some patients relapse when cyclosporine is tapered, and a minority later develop clonal evolution to PNH, myelodysplastic syndrome, or acute leukemia, which is why long-term follow-up with regular blood counts is essential.
Key Takeaways
- Confirm the diagnosis and exclude inherited causes before choosing treatment.
- Severity grading determines how urgently definitive treatment is needed.
- Stem cell transplant is the only cure and is favored for younger patients with a matched sibling.
- ATG plus cyclosporine, usually with eltrombopag, is standard for those not proceeding to transplant.
- Supportive care and long-term monitoring are essential with either approach.
For related reading on blood count problems, see our anemia guide.
Frequently Asked Questions
Can aplastic anemia be cured?
Yes. Stem cell transplantation can cure aplastic anemia, and many patients treated with immunosuppressive therapy achieve long-lasting remission with near-normal blood counts. The best approach depends on age, severity, and donor availability.
How long does it take for ATG and cyclosporine to work?
Counts usually start to improve after a few months, with most responses evident within three to six months. Transfusion support continues until counts recover, so patience during this period is important.
Is aplastic anemia a type of cancer?
No. Aplastic anemia is a form of bone marrow failure, not a cancer. However, a small proportion of patients later develop myelodysplastic syndrome or leukemia, which is one reason for regular follow-up.
Should I avoid anything during treatment?
Avoid known marrow toxins, such as unnecessary medications and chemical solvents, and discuss any new drug with your hematologist. When counts are very low, take care to prevent infection and injury, and seek urgent care for fever or bleeding.
